Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ).
From the U.S. FDA-approved label for Amphotericin B. Full label: DailyMed.
Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication.
From the U.S. FDA-approved label for Amphotericin B. Full label: DailyMed.
Amphotericin B liposome for injection is not interchangeable or substitutable on a mg per mg basis with other amphotericin B products. Different amphotericin B products are not equivalent in terms of pharmacodynamics, pharmacokinetics and dosing. Amphotericin B liposome for injection should be administered by intravenous infusion, using a controlled infusion device, over a period of approximately 120 minutes.
Directions from the U.S. FDA-approved label for Amphotericin B — your doctor or pharmacist may advise differently.
Amphotericin B liposome for injection is contraindicated in those patients who have demonstrated or have a known hypersensitivity to amphotericin B deoxycholate or any other constituents of the product unless, in the opinion of the treating physician, the benefit of therapy outweighs the risk.
Excerpt from the U.S. FDA-approved label for Amphotericin B. Talk to a pharmacist or doctor before use.
Anaphylaxis has been reported with amphotericin B deoxycholate and other amphotericin B-containing drugs, including amphotericin B liposome for injection. If a severe anaphylactic reaction occurs, the infusion should be immediately discontinued and the patient should not receive further infusions of amphotericin B liposome for injection.
Warnings and precautions excerpt from the U.S. FDA-approved label for Amphotericin B — not a complete list. Talk to a pharmacist or doctor before use.
The following adverse events are based on the experience of 592 adult patients (295 treated with amphotericin B liposome for injection and 297 treated with amphotericin B deoxycholate) and 95 pediatric patients (48 treated with amphotericin B liposome for injection and 47 treated with amphotericin B deoxycholate) in Study 94-0-002, a randomized double-blind, multi-center study in febrile, neutropenic patients.
Excerpt from the U.S. FDA-approved label for Amphotericin B — not a complete list. Talk to a pharmacist or doctor about side effects.
9 brands · 6 makers in the NepalDoc catalog — see the full Amphotericin B guide →
What is Mycol?
Mycol 500mg Injection is a Amphotericin B medicine made by Anglo-French Drugs & Industries Ltd. It comes as 500mg Injection.
What is Mycol used for?
According to its FDA label, Amphotericin B is used for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients.
What is the generic name of Mycol?
The generic name of Mycol is Amphotericin B.
Which brands of Amphotericin B are available in Nepal?
9 brands of Amphotericin B are listed in the NepalDoc catalog, from 6 makers — including Amfy 50mg Injection, Amphonex 50mg Injection, Amphotericin B 50mg Injection, Amphotret 50mg Injection, Fungizone 50mg Injection, Lambin 10mg Injection.
What are the side effects of Amphotericin B?
The following adverse events are based on the experience of 592 adult patients (295 treated with amphotericin B liposome for injection and 297 treated with amphotericin B deoxycholate) and 95 pediatric patients (48 treated with amphotericin B liposome for injection and 47 treated with amphotericin B deoxycholate) in Study 94-0-002, a randomized double-blind, multi-center study in febrile, neutropenic patients.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. A catalog listing does not guarantee that a medicine is in stock at any pharmacy.
Every NepalDoc section, one tap away.
Find doctors by specialty across Nepal.
